BACKGROUND: Myeloperoxidase (MPO) has been listed as a potentially useful risk marker in acute coronary syndrome. However, its clinical utility in patients with acute chest pain is not yet defined. DESIGN AND METHODS: MPO (Architect, Abbott Diagnostics) was measured in 120 healthy controls and 303 chest pain patients who had been admitted to the coronary care units of three Swedish hospitals. RESULTS: Chest pain patents had significantly higher median MPO levels compared to healthy controls (120.6 vs. 78. 9 pmol/L; p<0.001). However, MPO was not useful for the diagnosis of myocardial infarction (c-statistics 0.61 [95% CI 0.54-0.67]), and Cox regression analysis revealed no independent association between MPO and mortality (adjusted hazard ratio 1.3 [95% CI 0.8-2.0]) or the composite endpoint (adjusted hazard ratio 1.1 [95% CI 0.8-1.5]) after a median follow-up of 4.9 years. CONCLUSIONS: MPO provided no clinically relevant information in the present population of chest pain patients. (c) 2009 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
BACKGROUND:Myeloperoxidase (MPO) has been listed as a potentially useful risk marker in acute coronary syndrome. However, its clinical utility in patients with acute chest pain is not yet defined. DESIGN AND METHODS: MPO (Architect, Abbott Diagnostics) was measured in 120 healthy controls and 303 chest painpatients who had been admitted to the coronary care units of three Swedish hospitals. RESULTS:Chest pain patents had significantly higher median MPO levels compared to healthy controls (120.6 vs. 78. 9 pmol/L; p<0.001). However, MPO was not useful for the diagnosis of myocardial infarction (c-statistics 0.61 [95% CI 0.54-0.67]), and Cox regression analysis revealed no independent association between MPO and mortality (adjusted hazard ratio 1.3 [95% CI 0.8-2.0]) or the composite endpoint (adjusted hazard ratio 1.1 [95% CI 0.8-1.5]) after a median follow-up of 4.9 years. CONCLUSIONS:MPO provided no clinically relevant information in the present population of chest painpatients. (c) 2009 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
Authors: Peter A Kavsak; Andrew Worster; John J You; Mark Oremus; Adell Elsharif; Stephen A Hill; P J Devereaux; Andrew R MacRae; Allan S Jaffe Journal: Clin Biochem Date: 2009-12-21 Impact factor: 3.281
Authors: Stephen J Nicholls; W H Wilson Tang; Danielle Brennan; Marie-Luise Brennan; Shirley Mann; Steven E Nissen; Stanley L Hazen Journal: Clin Chem Date: 2011-09-22 Impact factor: 8.327
Authors: Julia Searle; Jessie Shih; Reinhold Muller; Jörn O Vollert; Christian Müller; Oliver Danne; Saul Datwyler; Martin Möckel Journal: Eur Heart J Acute Cardiovasc Care Date: 2013-09
Authors: Andrew R Kolodziej; Mohamed Abo-Aly; Eman Elsawalhy; Charles Campbell; Khaled M Ziada; Ahmed Abdel-Latif Journal: Mediators Inflamm Date: 2019-06-25 Impact factor: 4.711